
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial.
Versus Systems Inc. develops and operates a business-to-business software platform that enables video game publishers and developers to deliver prize-based matches of their games to their players in Canada and the United States. The company is headquartered in Vancouver, Canada.
| Revenue (TTM) | $2.00M |
| Gross Profit (TTM) | $1.99M |
| EBITDA | $-2.16M |
| Operating Margin | -4732.00% |
| Return on Equity | -92.00% |
| Return on Assets | -51.50% |
| Revenue/Share (TTM) | $0.41 |
| Book Value | $1.96 |
| Price-to-Book | 0.85 |
| Price-to-Sales (TTM) | 4.22 |
| EV/Revenue | 3.855 |
| EV/EBITDA | -0.86 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -91.30% |
| Shares Outstanding | $6.21M |
| Float | $1.76M |
| % Insiders | 50.62% |
| % Institutions | 0.62% |
Volatility is currently contracting

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial.

Discover why Zacks rates Versus as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore VS' improving cash flow and tighter cost controls amid customer concentration and profitability challenges.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VS and any ticker you trade — then tracks every position and per-strategy win rate.